natgillin/translations-raw huggingface dataset:
Paxene should not be used in people who may be hypersensitive (allergic) to paclitaxel or any of the other ingredients. 
Paxenet ei tohi kasutada patsiendid, kes võivad olla paklitakseeli või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
Treatment with Paxene should be given by an oncologist (cancer specialist) in a specialised cancer ward. 
Paxenet tohib manustada ainult onkoloog (vähiravi spetsialist) vähiravile spetsialiseerunud osakonnas.
Paxene is an anticancer medicine. 
Paxene on vähiravim.
The Committee for Medicinal Products for Human Use (CHMP) decided that Paxene's benefits are greater than its risks for treatment of advanced AIDS-related Kaposi's sarcoma, metastatic breast cancer, advanced cancer of the ovary in combination with cisplatin, metastatic cancer of the ovary where platinum-containing combination therapy has failed, and non-small cell lung cancer. 
Inimravimite komitee otsustas, et Paxene kasulikkus AIDSiga seotud kaugelearenenud Kaposi sarkoomi, metastaasidega rinnanäärmevähi, kaugelearenenud munasarjavähi, kombinatsioonis tsisplatiiniga kaugelearenenud munasarjavähi, plaatinat sisaldava kombinatsioonravi ebaõnnestumise järgselt metastaasidega rinnanäärmevähi või mitteväikerakk-kopsuvähiga patsientidel on suurem kui sellega kaasnevad riskid.
What benefit has Paxene shown during the studies? 
Milles seisneb uuringute põhjal Paxene kasulikkus?
• non-small cell lung cancer, in combination with cisplatin, when patients cannot have surgery or radiation therapy. 
• kombinatsioonis tsisplatiiniga mitteväikerakk-kopsuvähi raviks patsientidel, kellele ei ole näidustatud kirurgiline ravi ja/või kiiritusravi.
Treatment with Paxene improved the response rates for various types of cancer. 
Ravi Paxenega parandas eri vähivormide ravivastuse määra.
For the full list of all side effects reported with Paxene, see the Package Leaflet. 
Paxene kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
The full EPAR for Paxene is available here. 
Euroopa avaliku hindamisaruande täisteksti Paxene kohta leiate siit.
The dose of Paxene, how often it is given and how long treatment continues depend on the type of cancer being treated and which other anticancer medicines are being given together with Paxene. 
Paxene annus, manustamise sagedus ja ravi kestus oleneb ravitava vähi vormist ja lisaks Paxenele manustatavatest vähiravimitest.
• metastatic cancer of the ovary, when other treatments such as platinum-containing combination therapy have failed; 
• metastaasidega munasarjavähi raviks teiste raviskeemide (näiteks plaatinapreparaate sisaldav kombinatsioonravi) ebaõnnestumise järgselt;
What is Paxene used for? 
Milleks Paxenet kasutatakse?
How does Paxene work? 
Kuidas Paxene toimib?
Paclitaxel blocks the cell's ability to break down the ‘skeleton' that allows cells to divide and multiply. 
Paklitakseel pärsib raku võime lagundada raku sisetoest, et rakk saaks jaguneda ja paljuneda.
It contains the active substance paclitaxel. 
Paxene sisaldab toimeainena paklitakseeli.
It must not be used in women who are pregnant or breastfeeding. 
Rasedad või imetavad patsiendid Paxenet kasutada ei tohi.
Paxene also increased how long patients survived for some types of cancer. 
Mõnede vähivormide korral pikendas Paxene patsientide elulemust.
• advanced AIDS-related Kaposi's sarcoma (a skin cancer often found in AIDS patients), when treatment with anthracyclines (another type of anticancer medicine) has failed; 
• AIDSiga seotud kaugelearenenud Kaposi sarkoomi (AIDSiga patsientidel sageli esinev nahavähk)
• advanced cancer of the ovary (when the cancer has started to spread out of the ovary), in combination with cisplatin (another anticancer medicine); 
• kombinatsioonis tsisplatiiniga (samuti vähiravim) kaugelearenenud munasarjavähi (vähk on levinud organismis ka mujale) raviks;
The active substance in Paxene, paclitaxel, belongs to the group of anticancer medicines known as the taxanes. 
Paxene toimeaine paklitakseel kuulub vähiravimite taksaanide rühma.
How is Paxene used? 
Kuidas Paxenet kasutatakse?
How has Paxene been studied? 
Kuidas Paxenet uuriti?
Sanofi-Aventis France 
Sanofi-Aventis Prantsusmaa
Aurovitas Spain,s.A.U. 
Aurovitas Hispaania,s.A.U.
Roche Romania Srl 
Roche Rumeenia Srl
Meda Pharma Hungary Kft. 
Meda Pharma Ungari Kft.
Adapalene 1mgg 
Adapaleen 1mgg
Roche Bulgaria Eood Roaccutane 
Roche Bulgaaria Eood Roaccutane
Pierre Fabre Hellas / Greece 
Pierre Fabre Hellas / Kreeka
Arrow Generiques Acnetrait 
Arrow Generiques
Tretinoina Same Savoma Medicinali 
Savoma Medicinali Spa Tretinoina Same Savoma Medicinali
Pierre Fabre Iberica / Spain 
Pierre Fabre Iberica / Hispaania
Roche (Magyarország) Kft Roaccutan 
Roche (Magyarország) Kft
Stiefel Laboratories (Ireland) Ltd 
Stiefel Laboratories (Iirimaa) Ltd
Genus Pharmaceuticals 
Acitretin Genus Pharmaceuticals
Teva Magyarország Zrt 
Teva Magyarország Zrt Isotretinoin Teva
Laboratorios Galderma SaSucursal Em Portugal 
Laboratorios Galderma Sa - Sucursal Em Portugal
Ratiopharm Arzneimittel Vertriebs-Gmbh 
Ratiopharm Arzneimittel VertriebsGmbh
Pharmaceuticals Ireland 
Allergan Pharmaceuticals Iirimaa
Pharmaceuticals Limited 
Genus Pharmaceuticals Limited
Isotretinoin Generics [uk] 
Generics [uk] Limited Isotretinoin Generics [uk]
Galderma (Uk) Limited 
Galderma (Uk) Limited Differin
Tretinoin 500µg G 
Tretinoiin 500µg G
Laboratoires Bailleul Sa 
Laboratoires Bailleul Sa Erylik
Mg 
Kg
Tretinoin 0.1g 
Tretinoiin 0.1g
Isotretinoin Ranbaxy (Uk) 
Ranbaxy (Uk) Limited Isotretinoin Ranbaxy (Uk)
Pharmaceuticals Polska Sp. Z O.O. 
Teva Pharmaceuticals Polska Sp. Z O.O.
Tretinoin 0.3mg G, Urea 120mg G 
Tretinoiin 0.3mg G, Urea 120mg G
Dexpanthenol 0.1mg G, Tretinoin 3µg G, Urea 1.2mg G 
Dexpanthenol 0.1mg G, Tretinoiin 3µg G, Urea 1.2mg G
Societe D'etudes Et De Recherches Pharmaceutiques (Serp) 
Societe D'etudes Et De Recherches
Isotretinoin 20mgg 
Isotretinoiin 20mgg
United Kingdom Sandoz Ltd 
Sandoz Ltd
Almirall Hermal Gmbh 
Almirall Hermal Gmbh Aknenormin
Adapalene 0.1%w/W Cream 
Adapaleen 0.1%w/W Kreem
Tretinoin 0.05g 
Tretinoiin 0.05g
Glaxosmithkline Slovakia S.R.O. 
Glaxosmithkline Slovakkia S.R.O.
Tretinoin 15mg/30 G Cream 
Tretinoiin 15mg/30 G Kreem
Isotretinoin 10mgg 
Isotretinoiin 10mgg
Adapalene Zentiva Adapalene 0.1% Cream 
Adapalene Zentiva Adapaleen 0.1%
Acitretin 25mg Capsule Capsule 
Atsitretiin 25mg Kapsel
Glaxosmithkline Gmbh & Co. Kg 
Glaxosmithkline Gmbh & Co.
Tretinoin 0.05%w/W Gel 
Tretinoiin 0.05%w/W Geel
Dermapharm Ag Keraderm 
Dermapharm Ag
Topical Application 
Paikseks kasutamiseks
Roche Latvija Sia Roaccutane 
Roche Latvija Sia
Isotretinoin 0.05%w/W Gel 
Isotretinoiin 0.05%w/W Geel
Adapalene 1mg G 
Adapaleen 1mg G
Isotretinoin 20mg 
Isotretinoiin 20mg
Glaxosmithkline Aebe 
Glaxosmithkline Aebe Cehado
Galderma International 
Galderma International Differine
Tretinoin 4mg G 
Tretinoiin 4mg G
Meda Pharma 
Meda Pharma Sas
Adapalène Zentiva Adapalene 0.1g/100 G Gel 
Adapalène Zentiva Adapaleen 0.1g/100 G Geel
Puren Pharma Gmbh & Co. Kg 
Puren Pharma Gmbh & Co.
Pharmaswiss česká Republika S.R.O. 
Pharmaswiss česká
Adapalene 0.1% Gel 
Adapaleen 0.1%
Nexus Medicals S.A. Accuran 
Nexus Medicals S.A.
Galderma Laboratorium Gmbh Epiduo 
Galderma Laboratorium Gmbh
Adapalene 0.1%w/W Gel 
Adapaleen 0.1%w/W Geel
Laboratório Medinfar - Produtos Farmacêuticos, S.A. 
Laboratório MedinfarProdutos Farmacêuticos, S.A.
Tazarotene 0.5mg G Gel 
Tazaroteen 0.5mg G Geel
Ziaja Ltd Zakład Produkcji Leków Sp Z O.O. 
Produkcji Leków Sp Z O.O.
Isotretinoin Ratiopharm Isotretinoin 20mg 
Isotretinoin Ratiopharm Isotretinoiin 20mg Kapsel
Isotretinoin Sandoz Isotretinoin 20mg 
Isotretinoïne Sandoz Isotretinoiin 20mg Kapsel
Erythromycin 4g/100 G, Tretinoin 0.025g/100 G Gel 
Erütromütsiin 4g/100 G, Tretinoiin 0.025g/100 G
Atrederm 0,05% 
Tretinoiin 0.05%
Sapiens Pharmaceuticals Ltd Rotren 
Sapiens Pharmaceuticals Ltd
Isotretinoin 0.5mg G Cream 
Isotretinoiin 0.5mg G Kreem
Glaxosmithkline (Cyprus) Limited Isotrexin 
Glaxosmithkline (Küpros) Limited
Adapalene Teva Adapalene 0.1g G 
Adapaleen 0.1g G
Tretinoin 1mg G 
Tretinoiin 1mg G
Adapalene 1mg G, Benzoyl Peroxide 25mg G 
Adapaleen 1mg G, Bensüülperoksiid 25mg G
Acitretin 10mg Capsule Capsule 
Atsitretiin 10mg Kapsel
Isotretinoin 0.05g/100 G Gel 
Isotretinoiin 0.05g/100 G Geel
Pharmathen Hellas S.A. 
Pharmathen Hellas S.A. A-Cnotren
Tretinoin 0.25mg G Cream 
Tretinoiin 0.25mg G Kreem
Actavis Group Ptc Acnenor 
Actavis Group Ptc Ehf.
Isotretinoin 0.5mgg 
Isotretinoiin 0.5mgg
Tazarotene 0.1mg/100 Gel 
Tazaroteen 0.1mg/100 Mg Geel
Tretinoin 0.5mg G 
Tretinoiin 0.5mg G
B.V. 
N.V.
Tazarotene 0.05g/100 G Gel 
Tazaroteen 0.05g/100 G Geel
Isotretinoin Ratiopharm 
Ratiopharm Gmbh Isotretinoiin Ratiopharm
Tretinoin 0.05g/100 Ml 
Tretinoiin 0.05g/100 Ml
Tretinoin 0.5mg/Ml 
Tretinoiin 0.5mg/Ml
Tazarotene 1mg G Gel 
Tazaroteen 1mg G
Isotretinoin 0.5mg 
Isotretinoiin 0.5mg
Adapalene 0.1g/100 G Cream 
Adapaleen 0.1g/100 G Kreem
N.V. Roche S.A. 
Roche S.A.
Tretinoin 500µg/Ml, DlAlpha Tocopherol Acetate 100µg/Ml 
Atrederm 0,05% Tretinoiin 500µg/Ml, Dl-Alfa tokoferoolatsetaat 100µg/Ml
Hydrocortisone 10mg G, Tretinoin 1mg G, 
Hydrocortisone 10mg G, Tretinoiin 1mg G, Hydroquinone 50mg G
Isotretinoin Puren 
Isotretinoina Stiefel
Tretinoin 0.025g/100 G Cream 
Tretinoiin 0.025g/100 G Kreem
Tazarotene 0.1g/100 G Gel 
Tazaroteen 0.1g/100 G Geel
Isotretinoin Actavis Isotretinoin 5mg Capsule Capsule, Soft 
Isotretinoin Actavis Isotretinoiin 5mg Kapsel
Alitretinoin 10mg 
Alitretinoiin 10mg Kapsel
Tretinoin 250µg/Ml, DlAlpha Tocopherol Acetate 50µg/Ml 
Atrederm 0.025% Tretinoiin 250µg/Ml, Dl-Alfa tokoferoolatsetaat 50µg/Ml
Meda Pharmaceuticals Ltd Atralin 
Meda Pharmaceuticals Ltd
Glaxosmithkline (Ireland) Limited Isotrexin 
Glaxosmithkline (Iirimaa) Limited
Tretinoin 10mg Capsule Capsule, Soft 
Tretinoiin 10mg Kapsel
Isotretinoin Teva 
Adapalene Teva
Acitretin 10mg Piece 
Atsitretiin 10mg
List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the member states for Retinoids containing medicinal products 
LISA I RIIKLIKU MÜÜGILOAGA RAVIMITE LOEND
Pharmachemie B.V Isotretinoïne Pch 
Pharmachemie B.V Isotretinoïne Pch Isotretinoiin 10mg Kapsel
Isotretinoin Jenson Isotretinoin 5mg Capsule Capsule, Soft 
Generics [uk] Limited Isotretinoin Jenson Isotretinoiin 5mg Kapsel
Adapalene 0.1g/100 G Gel 
Adapaleen 0.1g/100 G Geel
Bulgaria неотигазон 
неотигазон
Carbamid + Vas Creme 
Ureotop + Vas
Clindamycin Phosphate 10mg G, Tretinoin 0.25mg G 
Klindamütsiinfosfaat 10mg G, Tretinoiin 0.25mg G
Tretinoin 0.05g/100 G Cream 
Tretinoiin 0.05g/100 G Kreem
Erythromycin 20mgg, Isotretinoin 0.5mgg Gel 
Erütromütsiin 20mgg, Isotretinoiin 0.5mgg
Meda Pharma Sia Treclinac 
Meda Pharma Sia
Clindamycin 10mg G, Tretinoin 0.025mg G Gel 
Klindamütsiin 10mg G, Tretinoiin 0.025mg G
Tretinoin 0.5mg/Mg Cream 
Tretinoiin 0.5mg/Mg
Erythromycin 20mg G, Isotretinoin 0.05mg G Gel 
Erütromütsiin 20mg G, Isotretinoiin 0.05mg G
Isotretinoin 0.05mg G Gel 
Isotretinoiin 0.05mg G Geel
Clindamycin 10mg G, Tretinoin 0.25mg G Gel 
Klindamütsiin 10mg G, Tretinoiin 0.25mg G
Tretinoin 0.25mg/Mg Cream 
Tretinoiin 0.25mg/Mg
Erythromycin 20mg G, Isotretinoin 0.5mg G Gel 
Erütromütsiin 20mg G, Isotretinoiin 0.5mg G
Adapalene 0.1g/100g Gel 
Adapaleen 0.1g/100g
Ltd 
Leedu
Isosupra Lidose Isotretinoin 8mg Capsule Capsule, Hard 
Isotretinoína Aurovitas Isotretinoiin 10mg Kapsel
Laboratoires Smb S.A. 
Laboratoires Smb S.A. Isosupra Lidose
Aebe 
Zanea
Teva Magyarország Isotretinoin Teva Isotretinoin 20mg 
Isotretinoin Puren Isotretinoiin 20mg Kapsel
Alitretinoin 1mg G 
Isotretinoiin 1mg G
Meda Pharmaceuticals S.A. Acnatac 
Meda Pharmaceuticals S.A.
Orifarm Generics A/S 
Orifarm Generics A/S Isotretinoin Orifarm Isotretinoiin 10mg Kapsel
Panretin 
Atralin
Isotretinoin 0.5mg G Gel 
Isotretinoiin 0.5mg G Geel
Stiefel Laboratories Toctino 
Laboratoires Bailleul Sa Contracne
A-Cnotren 
Neotigason
Tretinoin 0.03g/100 G, Urea 12g/100 G 
Louis Widmer Gmbh At Keratosis + Tretinoin Tretinoiin 0.03g/100 G, Urea 12g/100 G
Isotretinoin 10mg 
Isotretinoiin 5mg
Targretin 
Taani
The European Commission granted a conditional marketing authorisation valid throughout the European Union for Diacomit on 4 January 2007. 
Euroopa Komisjon andis Diacomiti tingimusliku müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 4. jaanuaril 2007.
The dose of valproate does not normally need to be adjusted. 
Valproaadi annust kohandada ei ole tavaliselt vaja.
It is available as capsules and sachets (250 and 500 mg). 
Seda turustatakse kapslitena ja kotikestena (250 mg ja 500 mg).
This type of epilepsy first appears in young children during the first year of life. 
Seda liiki epilepsia ilmneb esimesel eluaastal.
This was switched to a full marketing authorisation on 8 January 2014. 
Tingimuslik müügiluba muudeti tavaliseks müügiloaks 8. jaanuaril 2014.
Other information about Diacomit 
Muu teave Diacomiti kohta
Diacomit has been studied in two main studies involving 65 children between three and 18 years of age. 
Diacomiti on uuritud kahes põhiuuringus, milles osales 65 last vanuses 3-18 aastat.
EPAR summary for the public stiripentol 
Kokkuvõte üldsusele stiripentool
GABA is the main substance in nerve cells responsible for reducing the electrical activity of the brain. 
GABA on peamine aine närvirakkudes, mis vähendab aju elektrilist talitlust.
Treatment starts with a dose of 20 mg per kg bodyweight, which is gradually increased to the recommended dose over a number of weeks depending on the patient's age. 
Ravi alustatakse annusega 20 mg/kg, mida suurendatakse mitme nädala jooksul järk-järgult soovitatava annuseni, olenevalt patsiendi vanusest.
Care must be taken when Diacomit is used at the same time as other medicines. 
Ettevaatlik peab olema Diacomiti kasutamisel koos teiste ravimitega.
Diacomit was originally given ‘conditional approval' because there was more evidence to come about the medicine, in particular regarding its short-term and long-term effectiveness and safety. 
Diacomiti müügiluba anti esialgu tingimuslikult, sest ravimi ja eelkõige selle lühiajalise ja pikaajalise efektiivsuse ja ohutuse kohta oodati täiendavaid andmeid.
After starting Diacomit, the dose of clobazam may need to be reduced. 
Pärast Diacomitiga ravi alustamist võib olla vaja vähendada klobasaami annust.
The main measure of effectiveness was the number of patients who ‘responded' to treatment. 
Efektiivsuse põhinäitaja oli patsientide arv, kelle haigus allus ravile.
It is also known to amplify the effects of other anti-epileptic medicines and to slow down the rate at which they are broken down by the liver. 
On ka teada, et see tugevdab teiste epilepsiaravimite toimet ja aeglustab nende lagunemist maksas.
Diacomit should be given at the same time as food, but not with dairy products, carbonated drinks, fruit juice, or food or drinks that contain caffeine or theophylline (a substance found in black and green tea, among other products). 
Diacomiti tuleb anda koos toiduga, kuid mitte koos piimatoodete, gaseerjookide ega puuviljamahlaga või kofeiini või teofülliini (sisaldub muu hulgas mustas ja rohelises tees) sisaldavate toiduainete või jookidega.
The main studies of Diacomit were in children over three years of age. 
Diacomiti põhiuuringutes osalesid üle 3-aastased lapsed.
The summary of the opinion of the Committee for Orphan Medicinal Products for Diacomit can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations. 
Harvikravimite komitee arvamuse kokkuvõte Diacomiti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
It decided that Diacomit's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Komitee otsustas, et Diacomiti kasulikkus ületab sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The full EPAR for Diacomit can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Euroopa avaliku hindamisaruande täistekst Diacomiti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Diacomit is an anti-epileptic medicine that contains the active substance stiripentol. 
Diacomit on epilepsiaravim, mis sisaldab toimeainena stiripentooli.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Diacomit. 
Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
The CHMP concluded that Diacomit had shown its effectiveness in SMEI, albeit studies were limited and did not last as long as the Committee expected. 
Inimravimite komitee järeldas, et Diacomiti efektiivsus lapseea raske müokloonilise epilepsia ravimisel on tõestatud, kuigi uuringud olid piiratud ja nende kestus ei vastanud komitee ootustele.
What is the risk associated with Diacomit? 
Mis riskid Diacomitiga kaasnevad?
For more information about treatment with Diacomit, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Kui vajate Diacomitiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
Diacomit must not be used in patients who have had psychoses (a serious mental state with a distorted sense of reality) with attacks of delirium (a mental state with confusion, excitement, restlessness and hallucinations). 
Diacomiti ei tohi kasutada patsiendid, kellel on esinenud psühhoose (raske vaimuseisund, mille korral reaalsuse tunnetus on häiritud), millega on kaasnenud deliirium (vaimuseisund, mida iseloomustavad segasus, ärevus, rahutus ja hallutsinatsioonid).
Decisions regarding the use of Diacomit in younger children should be made on a patient-by-patient basis: it can only be given to younger children if the diagnosis of SMEI has been confirmed. 
Noorematel lastel tuleb Diacomiti kasutamise otsus teha iga patsiendi kohta eraldi: noorematele lastele tohib seda anda ainult siis, kui lapseea raske müokloonilise epilepsia diagnoos on kinnitatud.
Similar results were seen in the second study, with 67% responding to Diacomit (8 out of 12) and 9% to placebo (1 out of 9). 
Teise uuringu tulemused olid sarnased: ravivastusega patsiente oli Diacomiti rühmas 67% (8 patsienti 12st) ja platseeborühmas 9% (1 patsient 9st).
This is a summary of the European public assessment report (EPAR) for Diacomit. 
See on ravimi Diacomit Euroopa avaliku hindamisaruande kokkuvõte.
A patient was classified as a ‘responder' if the number of seizures in the second month of treatment was at least 50% lower than the number in the month before treatment was started. 
Ravivastuseks loeti epilepsiaepisoodide arvu vähenemist patsiendil Diacomitiga ravimise teisel kuul vähemalt 50% võrra võrreldes Diacomitiga ravi alustamisele eelnenud kuuga.
The most common side effects with Diacomit (seen in more than 1 in 10 patients) are loss of appetite, weight loss, insomnia (difficulty sleeping), drowsiness, ataxia (inability to co-ordinate muscle movements), hypotonia (low muscle strength) and dystonia (muscle disorders). 
Diacomiti kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on isutus, kehakaalu vähenemine, unetus, uimasus, ataksia (liigutuste koordinatsioonihäired), hüpotoonia (lihasnõrkus) ja düstoonia (lihastoonuse häired).
In the first study, 71% of the patients taking Diacomit responded to treatment (15 out of 21), compared with 5% of the placebo group (1 out of 20). 
Ravivastusega patsiente oli esimeses uuringus Diacomiti võtnud patsientidest 71% (15 patsienti 21st) ja platseeborühmas 5% (1 patsient 20st).
The recommended dose is 50 mg per kilogram bodyweight, divided into two or three doses during the day. 
Soovitatav annus on 50 mg kehamassi kg kohta (mg/kg) ööpäevas, jagatuna 2 või 3 annuseks.
The sachets contain a powder that is used to make up an oral suspension (a liquid with solid particles in it). 
Kotikesed sisaldavad pulbrit, millest valmistatakse suukaudne suspensioon (tahkeid osakesi sisaldav vedelik).
It has been shown in experimental models to increase the levels of a ‘neurotransmitter' called gamma aminobutyric acid (GABA) in the brain. 
Katsemudelites on tõendatud, et see suurendab neurotransmitteri gammaaminovõihappe (GABA) sisaldust ajus.
What is Diacomit? 
Mis on Diacomit?
Why has Diacomit been approved? 
Miks Diacomit heaks kiideti?
The exact way in which stiripentol, the active substance in Diacomit, acts as an anti-epileptic medicine is not fully known. 
Diacomiti toimeaine stiripentooli täpne toimemehhanism epilepsiaravimina ei ole täielikult teada.
See the package leaflet for the full list of restrictions. 
Piirangute täielik loetelu on pakendi infolehel.
For the full list of all side effects reported with Diacomit, see the package leaflet. 
Diacomiti kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
The studies compared Diacomit capsules or sachets with placebo (a dummy treatment), when they were added to the children's existing treatment with clobazam and valproate. 
Uuringutes võrreldi Diacomiti (kapslid või kotikesed) platseeboga (näiv ravim) nende lisamisel laste senisele ravile klobasaami ja valproaadiga.
Because the number of patients with SMEI is low, the disease is considered ‘rare', and Diacomit was designated as an ‘orphan medicine' (a medicine used in rare diseases) on 5 December 2001. 
Et lapseea raske müokloonilise epilepsiaga patsiente on vähe ja see haigus esineb harva, nimetati Diacomit 5. detsembril 2001 harvikravimiks.
Diacomit is used in children with a very rare type of epilepsy called ‘severe myoclonic epilepsy in infancy' (SMEI), also known as Dravet's syndrome. 
Diacomiti kasutatakse lastel väga harvaesinevat tüüpi epilepsia - lapseea raske müokloonilise epilepsia ehk Dravet' sündroomi raviks.
Treatment with Diacomit should only be given under the supervision of a doctor who specialises in the diagnosis and management of epilepsy in children (a paediatrician or paediatric neurologist). 
Diacomiti tohib anda üksnes laste epilepsia diagnostika ja ravi eriarsti (pediaatri või lasteneuroloogi) järelevalve all.
More patients responded to treatment with Diacomit than to placebo. 
Diacomiti rühmas oli ravivastusega patsiente rohkem kui platseeborühmas.
Diacomit is used as an add-on to clobazam and valproate (other anti-epileptic medicines) to treat generalised tonic-clonic seizures (major fits, including loss of consciousness) when these are not adequately controlled with clobazam and valproate. 
Diacomiti kasutatakse lisaks klobasaamile ja valproaadile (samuti epilepsiaravimid) generaliseerunud toonilis-klooniliste episoodide raviks (rasked epilepsiaepisoodid, millega kaasneb teadvusekaotus), mis piisavalt ei allu ravile klobasaami ja valproaadiga.
What benefit has Diacomit shown during the studies? 
Milles seisneb uuringute põhjal Diacomiti kasulikkus?
What is Diacomit used for? 
Milleks Diacomiti kasutatakse?
How has Diacomit been studied? 
Kuidas Diacomiti uuriti?
How does Diacomit work? 
Kuidas Diacomit toimib?
How is Diacomit used? 
Kuidas Diacomiti kasutatakse?
The medicine can only be obtained with a prescription. 
Diacomit on retseptiravim.
150 (3x50) tablets multipack 
150 (3x50) tabletti, multipakend
Powder for oral suspension bottle (HDPE) 
Pudel (kõrgtihe polüetüleen)
Do not take a smaller amount. 
Ärge võtke väiksemat kogust.
In particular: 
Eelkõige:
This will usually take about two minutes. 
Selleks kulub tavaliselt umbes kaks minutit.
Subsequent treatment should be symptomatic and supportive. 
Järgnev ravi peab olema sümptomaatiline ja toetav.
However, no systematic data are available. 
Süsteemseid andmeid ei ole aga saadaval.
The relevance of this to man has not been established. 
Selle tähtsus inimesele ei ole tõestatud.